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with neurological symptoms (partial crises in right face). MNRI evidences four lesions in brain and a lot of small intraduralis and
extramedullaris nodules. The big one was removed. The others lesions were treated though craniospinal irradiation (30Gy, 2Gy
per fraction except previous irradiated areas) and radiosurgery in brain lesions.
Conclusions. Myxopapillary ependymoma is a slowly growing, grade I tumour, they have a tendency to affect younger individuals
(mean age 36.4 years) and the vast majority are restricted to the conus medullaris and ﬁlum terminale. The recurrences are
usually conﬁned to the same site as the primary. Myxopapillary ependymomas have been rarely documented to metastasize,
both intra- and extracranially, but these are cases with a long clinical history with local recurrences. Finally, the facts that we
explain in this case show that we have to make a higher follow-up to avoid late recurrences despite some papers recommend
approximately 10 years.
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Introduction. Bevacizumab is a monoclonal antibody which inhibits VEGF, normalizes vascular permeability and improve edema.
Currently is indicated for the treatment of many solid tumors. In recent years it has been used for the treatment of brain
radionecrosis. The high-grade gliomas express high levels of VEGF and after use of bevacizumab have been observed rapid effect
on the improvement of neurological functions, allowing lower doses of corticosteroids.
Patients and methods. We used bevacizumab in a patient under compassionate use in our center for the treatment of brain
radionecrosis.
Results. 53-year old woman with no relevant medical history was diagnosed of grade II astrocytoma three years ago. The
patient underwent partial resection of the lesion, subsequently receiving radiotherapy dose 50.8Gy. After such treatment
continues follow up. In November 2010 she entered the area of internal medicine secondary to worsening neurological func-
tions. Radiological study was performed showing an extensive radionecrosis after radiotherapy with associated edema. Despite
the use of high-dose corticosteroids she was admitted again two months later. We offer treatment for radionecrosis to the
patient with bevacizumab under compassionate use procedure. The response of the patient after the ﬁrst administration
is excellent with improvement of neurological functions and without use of corticosteroids. She had four sessions of the
treatment, ending in April 2011. Later she carried on periodic reviews and in April 2012, presents a new radiological wors-
ening. We decide to begin a new treatment with bevacizumab. Again the patient showed clinical response with improvement
of neurological functions and currently continues periodic revisions without tumor progression and with a good quality of
life.
Conclusions. Bevacizumab can be considered as alternative therapy for the treatment of cerebral radionecrosis as it improves the
symptoms of patients and allows reduced use of corticosteroids.
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Introduction. Standard treatment in high grade astrocytomas (HGA) consists of maximal surgical resection, followed by
radiotherapy plus concomitant and adjuvant temozolomide. When relapse or progression occurs, there is no standard
treatment.
Objectives. To analyze the efﬁcacy (overall survival, OS and progression-free survival, PFS) and toxicity of treatment with beva-
cizumab plus irinotecan in patients with HGA in progression after radiotherapy and temozolomide.
Material and methods. Between January 10 and December 12, 15 patients, median age 50±6.4 (43–64), were analyzed retrospec-
tively. 73.3%men and 26.7%women. Complete resection: 8 (53.3%), partial resection: 5 (33.3%) and biopsy: 2 (13.3%). 7 had received
Gliadel® wafer placed in the resection cavity. Histological diagnosis: glioblastoma multiforme (14 patients) and 1 anaplastic astro-
cytoma. Median KPS 90. All patients had received prior radiotherapy with concurrent temozolomide (Stupp regimen). Median of
6±6 cycles (1–26) of adjuvant temozolomide. 7 patients (46.7%) were treated with the extended-schedule dose-dense temozolo-
mide, median of 4±2 cycles (1–7). Bevacizumab was administered with irinotecan every 2 weeks. Patients received treatment
until evidence of progression or unacceptable toxicity. Response was determined by MRI or clinical. Median of 13±12 cycles
(2–50). Mean and standard deviation for quantitative variables and absolute frequency and percentage for qualitative variables
were obtained. The Kaplan–Meier method was used to estimate patient survival.
Results. With a median follow-up of 7 months, 33.3% of patients had progressed and 40% had died. Median OS, 13.6 months. 6-
month OS, 84.6%. Median PFS, 7.2 months. PFS-6, 77%. Median time to progression was 6.6 months. Overall response: 6 patients
(40%), (complete in 2). Stabilization was observed in 3 patients, 3 progression and 3 clinical response. Toxicity: hypertension (2
patients), ﬁstula rectal bleeding (1 patient), and abdominal perforation (1 patient).
